首页> 外国专利> Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ECM, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds

Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ECM, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds

机译:对羊膜流体细胞衍生的ECM,细胞构建体的成熟的方法,对药物化合物的心脏毒性和流动筛选的用途

摘要

Disclosed herein are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed herein is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed herein are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.
机译:本文公开了使用从羊水(AFC-ECM)分离的体外衍生的细胞衍生的细胞外基质的方法,用于衍生自人诱导的多能干细胞(未成熟HIPSC-CM)在培养成熟中的未成熟心肌细胞的成熟 心肌细胞。 本文还公开了一种细胞构建体,其包含对这些成熟的心肌细胞的单层,用于对药物化合物的心脏毒性和/或逆失性筛选测定的AFC-ECM。 本文还公开了用于使用这种细胞构建体在体外测定药物化合物的心脏毒性和/或逆失性效果的方法。

著录项

  • 公开/公告号US11220671B2

    专利类型

  • 公开/公告日2022-01-11

    原文格式PDF

  • 申请/专利权人 STEMBIOSYS INC.;

    申请/专利号US202016797945

  • 申请日2020-02-21

  • 分类号C12N5/077;G01N33/50;

  • 国家 US

  • 入库时间 2022-08-24 23:18:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号